1-4 of 4
Kimberly Bogard
Close
Sort by
Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Saulius K. Girnius, Joshua Richter, Kimberly Bogard, Habte A. Yimer, Sudhir Manda, Roger M. Lyons, Stephen J. Noga, Robert M. Rifkin
Journal: Blood
Blood (2023) 142 (Supplement 1): 6677.
https://doi.org/10.1182/blood-2023-179795
Published: 2023
Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Ruemu E. Birhiray, Robert M. Rifkin, Christopher A. Yasenchak, January Fields-Meehan, Roger M. Lyons, Ramalingham Ratnasabapathy, Kimberly Bogard, Kim Tran, Dasha Cherepanov, Stephen J. Noga, Saulius K. Girnius, Stephen J. Noga
Journal: Blood
Blood (2022) 140 (Supplement 1): 7322–7323.
https://doi.org/10.1182/blood-2022-163071
Published: 2022
Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons
Journal: Blood
Blood (2021) 138 (Supplement 1): 2726.
https://doi.org/10.1182/blood-2021-150094
Published: 2021
Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K. Girnius, MD, Habte A. Yimer, MD, Stephen J. Noga, MDPhD, Sudhir Manda, MD, Roger M. Lyons, MD, Kimberly Bogard, PharmD, Presley Whidden, Dasha Cherepanov, Vickie Lu, PhD, Jack Aiello, EE, MS, BS, Joshua R. Richter, MD, Robert M. Rifkin, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140482
Published: 2020